CareONE Concierge Launches Clinical Study for FDA Breakthrough Alzheimer's Device
核心洞察
CareONE Concierge (搜索) has launched a new research study evaluating NeuroEM Therapeutics (搜索)' TEMT-RF cap (搜索), a wearable device with FDA Breakthrough Device designation for treating Alzheimer's-related dementia.
The non-invasive device delivers electromagnetic waves to potentially break apart toxic protein oligomers of beta-amyloid and tau proteins that drive Alzheimer's disease progression.
The study targets individuals with mild to moderate Alzheimer's-related dementia, requiring participants to wear the device twice daily for one hour while completing cognitive assessments.
CareONE Concierge (搜索) has announced the launch of a clinical research study to evaluate an innovative wearable device for treating cognitive symptoms associated with Alzheimer's-related dementia. The study will utilize NeuroEM Therapeutics (搜索)' TEMT-RF cap (搜索), a non-invasive device that has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
Novel Electromagnetic Therapy Approach
The lightweight, wearable device delivers electromagnetic waves similar to those produced by cell phone signals from multiple emitters. The technology, known as Transcranial Electromagnetic Treatment using Radio Frequencies (TEMT-RF), is being investigated for its potential to break apart toxic protein oligomers within neurons throughout the brain.
These oligomers—clusters of beta-amyloid and tau proteins—are thought to drive the progression of Alzheimer's disease. By disrupting these harmful accumulations, TEMT-RF may help restore neuronal function and slow cognitive decline, representing a potentially groundbreaking approach to treating the disease at its root rather than merely addressing symptoms.
Study Design and Patient Population
The study is independently conducted by CareONE Concierge (搜索) and is designed for individuals with mild to moderate Alzheimer's-related dementia. Participants will be required to wear the device twice daily for one hour, follow a structured research protocol, and complete cognitive assessments throughout the study.
"We all know friends and family members who have been impacted by Alzheimer's or dementia," said Peter Bechtel, CEO of CareONE Concierge (搜索). "This study represents a potential turning point in the fight against these devastating conditions. By participating in this study, individuals have the opportunity to experience cutting-edge, non-drug therapy while contributing to groundbreaking advancements in Alzheimer's treatment."
Scientific Foundation and Clinical Significance
Dr. Edward Goodwin, Chief Scientist at NeuroEM, emphasized the scientific foundation behind TEMT-RF, stating, "Our research has shown that TEMT-RF has the potential to impact the key biological processes associated with Alzheimer's disease. This study will help us gather more real-world data on how the device affects cognitive function and overall brain health."
The research builds upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF). NeuroEM Therapeutics (搜索) received the first Breakthrough Device status from the FDA to treat Alzheimer's disease, highlighting the regulatory recognition of this novel therapeutic approach.
Addressing Growing Healthcare Crisis
Alzheimer's disease represents a growing global health crisis, affecting nearly 7 million Americans and projected to impact nearly 13 million by 2050. Despite decades of research, treatment options remain limited, with most current therapies only addressing symptoms rather than the underlying causes of cognitive decline.
"NeuroEM is excited to partner with CareONE Concierge (搜索)," stated Chuck Papageorgiou, CEO of NeuroEM Therapeutics (搜索). "Our objective is to promote safe, effective, and non-invasive technologies for cognitive health, and research initiatives like this are essential in helping us uncover the full potential of TEMT-RF. With Alzheimer's cases increasing, innovative research such as this provides new hope for patients, caregivers, and the future of cognitive health."
Study Participation and Next Steps
CareONE Concierge (搜索) is now accepting qualified participants for the study. The company is committed to delivering preventative healthcare solutions that meet the needs of patients, providers, and the healthcare system, working with physicians, patients, and healthcare systems to develop turnkey solutions that increase patient outcomes while enhancing revenue and quality metrics.
NeuroEM's continued dedication to cutting-edge research is bringing to market a first-in-class wearable device designed for in-home use to extend healthy longevity using patented TEMT-RF technology. The partnership represents a significant step toward developing non-invasive therapeutic options for neurodegenerative conditions.
For more information or to apply for study participation, interested individuals can contact the study team at CT@careone-concierge.com or apply at BestMindForMe.com.